-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $22

Benzinga·11/09/2026 13:05:11
Listen to the news
Citigroup analyst Geoff Meacham initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $22.